SERPINA12 antibody
- Known as:
- SERPINA12 (anti-)
- Catalog number:
- orb101158
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- SERPINA12 antibody
Related genes to: SERPINA12 antibody
- Gene:
- SERPINA12 NIH gene
- Name:
- serpin family A member 12
- Previous symbol:
- -
- Synonyms:
- OL-64, Vaspin
- Chromosome:
- 14q32.13
- Locus Type:
- gene with protein product
- Date approved:
- 2004-05-21
- Date modifiied:
- 2016-04-06
Related products to: SERPINA12 antibody
Related articles to: SERPINA12 antibody
- This study investigated the impact of human immunodeficiency virus (HIV) infection and combination antiretroviral therapy (cART) on adipokine concentrations, which are bioactive molecules secreted by adipose tissue and involved in the regulation of metabolism and inflammation. Alterations in adipokine levels may contribute to the metabolic disturbances observed in people living with HIV. The analyzed adipokine panel included resistin, visfatin, chemerin, angiopoietin-like protein 2 (ANGPTL2), lipocalin-2 (LCN2), Wnt family member 5A (Wnt5a), adiponectin, omentin, vaspin, secreted frizzled-related protein 5 (SFRP5), and apelin. Blood samples were collected from people living with HIV and HIV-negative control participants. Adipokine concentrations were measured using an enzyme-linked immunosorbent assay (ELISA). Patients were further stratified according to their cART regimen, including either protease inhibitor (PI)-based or integrase strand transfer inhibitor (INSTI)-based therapy. Plasma concentrations of ANGPTL2 and vaspin were significantly higher, whereas concentrations of visfatin, SFRP5, and adiponectin were significantly lower in HIV-infected patients compared with controls. Comparison of patients receiving INSTI- or PI-based regimens with the control group revealed significant differences in visfatin, SFRP5, and adiponectin concentrations. Notably, adiponectin concentrations were significantly lower in the INSTI-treated subgroup than in patients receiving PI-based therapy. These findings suggest that five of the examined adipokines may be associated with HIV infection and cART exposure, potentially contributing to the development of metabolic disturbances in this population. Further studies involving larger cohorts of individuals with HIV receiving long-term cART are required to better elucidate the relationship between adipokine alterations and the risk of treatment-related metabolic complications. - Source: PubMed
Publication date: 2026/08/01
Szymańska BeataKnysz BrygidaPiwowar Agnieszka - Adipose tissue has emerged as a pivotal endocrine organ, secreting bioactive proteins termed adipokines that regulate metabolic and immune processes across multiple organ systems. In the context of sepsis and critical illness, conditions defined by a dysregulated host response to infection with life-threatening organ dysfunction, the role of novel adipokines has attracted considerable research interest. This review focuses on three novel adipokines: chemerin, vaspin (), and omentin-1 (intelectin-1). We will discuss current in vitro, in vivo experimental animal models, and clinical evidence, emphasizing their biology, mechanisms of action, and potential as diagnostic and prognostic biomarkers in critically ill patients. All three adipokines are elevated in sepsis compared with healthy controls and correlate with established severity scores, including APACHE II and SOFA. Chemerin and omentin-1 have both been independently associated with 28-day mortality in prospective cohort studies. Vaspin exhibits robust cardioprotective effects in murine sepsis models via inhibition of kallikrein 7 (KLK7) and attenuates lipopolysaccharide (LPS)-induced acute lung injury (ALI) both in vitro and in vivo. Omentin-1 suppresses LPS-induced macrophage activation through TLR4/MyD88/NF-κB inhibition in vitro and protects against LPS-induced ALI in murine models. Despite these promising findings, substantial methodological heterogeneity and limited large-scale clinical data currently preclude clinical implementation. Future research that standardizes assays, expands to multicenter cohorts, and investigates therapeutic modulation of these pathways is urgently needed. - Source: PubMed
Publication date: 2026/07/10
Giannopoulou VassilikiPapavassiliou Kostas ALotsios Nikolaos SKardara MatinaKotanidou AnastasiaPapavassiliou Athanasios GDimopoulou IoannaVassiliou Alice G - Palmoplantar keratoderma (PPK) is a heterogeneous group of skin diseases, characterised by excessive keratinization and hyperplasia of the palms and soles. However, accurate molecular diagnosis remains challenging due to the low prevalence of hereditary forms. This study analysed the phenotype and genotype distribution in a large cohort of Chinese patients with PPK, aiming to clarify the genetic aetiology and genotype-phenotype correlations. We further validated the pathogenicity of biallelic SERPINA12 variants identified in four patients. A total of 424 patients with PPK were enrolled from 2010 to 2023. Of these, 97.6% (414/424) presented with diffuse PPK, predominantly Nagashima-type PPK (NPPK), with rare cases of Olmsted, Meleda and Bothnia types. Focal PPK accounted for 1.4%, with less than 1% for striate and punctate types, respectively. Genetic testing was performed in 380 patients. Overall, 328 patients harboured pathogenic or likely pathogenic (P/LP) variants to achieve definite molecular diagnosis; none carried only variants of uncertain significance (VUS) and the remaining 52 patients had no candidate disease-associated variants identified. All patients underwent testing with an in-house customised SERPINB7 gene hotspot panel test for c.796C>T, c.522_523insT, c.806_818delinsT and c.650_653delCTGT variants. In 80% (304/380) patients, hotspot variants in SERPINB7 were identified, with c.796C>T (77%) and c.522_523insT (16%) being the most frequent. Patients not diagnosed with a hotspot variant further underwent whole-exome sequencing (WES), which identified confirmed pathogenic (P) or likely pathogenic (LP) variants in TRPV3 (c.1246C>T, c.1703G>A, c.1247G>A), AQP5 (c.530 T>A, c.367A>T), SLURP1 (c.154A>G), KRT9 (c.1373 T>C), KRT6A (c.947G>C) and KRT16 (c.379C>T). In addition, three recurrent SERPINA12 variants were identified, enriching the gene spectrum of diffuse PPK. This study established the largest cohort of patients with SERPINB7 variants reported to date, identifying that NPPK is the predominant subtype among Chinese populations. Variants in SERPINA12 are likely correlated with diffuse palmoplantar keratoderma, consistent with the clinical manifestations of NPPK. Additionally, a diagnostic panel targeting ancestral SERPINB7 founder variants would markedly improve the molecular diagnostic yield in Chinese patients. - Source: PubMed
Wang XinyiSun WeiweiZhang ChengWang YumengLi MingyangGe HongsongZheng LuyaoCao QiaoyuLi YueWang ShucuiZhao AnqiPan ChaonanZeng YibinLi Ming - Interest in identifying biomarkers that reflect spine condition and support therapy monitoring has grown. Since low-grade inflammation and comorbidities can complicate treatment, they should be considered in research. Vaspin (SERPINA12) has been linked to low back pain (LBP) severity and disability, highlighting its potential as a biomarker connecting LBP and adipose tissue inflammation. The study aimed to assess the effect of traction therapy on serum vaspin levels and compare responses between women with obesity and normal BMI. A secondary aim was to explore associations between vaspin, LBP severity, disability scores, and selected inflammatory markers. It is a prospective clinical trial. Women aged 34-50 years with chronic LBP were divided into two groups: those with normal BMI and those with obesity. Both groups underwent 20 30-min sessions of lumbar traction therapy. At baseline and after therapy, LBP intensity, the Oswestry Disability Index (ODI), and the Roland-Morris Disability Questionnaire (RMDQ) were assessed, and blood samples were collected for analysis of vaspin, RANTES, interleukin (IL)-2, IL-17A, IL-4, and IL-10. After completing the traction therapy, there was a significant decrease in LBP, ODI, and RMDQ and an increase in the circulating levels of IL-10, regardless of BMI. However, vaspin concentration increased significantly only in women with normal BMI. Post-therapy, vaspin negatively correlated with ODI. IL-4 and IL-17A levels also correlated with vaspin, positively in women with normal BMI and negatively in those with obesity. Obesity-related inflammation may alter the biochemical response to traction therapy. Increases in vaspin concentration were found exclusively in women with normal BMI, indicating a possible BMI-dependent association between circulating vaspin concentrations and response to therapy.Registration: The study was registered at ClinicalTrials.gov with the ID number NCT04507074. - Source: PubMed
Publication date: 2026/06/29
Ratajczak MarzenaKalinkovich AlexanderLivshits Gregory - - Source: PubMed
Publication date: 2026/06/14
Pan LuluBu Zhangyu